MADD and neoplasm: In vivo, MADD siRNA-treated tumors (118.4 ± 43.18 mm3) had significantly reduced tumor volume as compared to untreated control (226.2 ± 79.62 mm3; P < 0.005) and scramble siRNA-treated tumors (254 ± 38.18 mm3; P = 0.0005) (Fig. 1d, e).